Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protectimmun Gets Positive Scientific Advice Response from EMA for Innovative Allergy Prophylaxis

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
Protectimmun GmbH has successfully discussed the overall clinical development plan for its innovative allergy prophylaxis against hay fever and allergic asthma.

The Agency agreed to the biological rationale of the allergy prevention concept and endorses the proposed key elements of the clinical safety and efficacy studies including study population, duration, and endpoints.

"We are very pleased to get this favourable opinion from EMA’s medical experts”, says Marion Kauth, CEO and co-founder of Protectimmun. "It is the reward for our efforts to elaborate the complete development plan for this first-in-class innovation at the earliest and to carefully consider the special issues for a preventive approach in children.”

Nose drops for the prevention of hay fever and asthma

Protectimmun is a pharmaceutical R&D company focussed on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Its lead development is a first-in-class medicinal product that may offer long-lasting protection against the development of hay fever and allergic asthma in infants. The product contains probiotic bacteria from a specific farm environment and will be applied as nose drops. Application via the nasal mucosa mimics the natural exposure of farm children by intensive barn contact in early life that has been shown to be allergy-protective in large epidemiological studies. More than 5 million infants would be eligible for this preventive treatment in Europe and the USA each year.

Professor Albrecht Bufe, paediatrician and co-founder of the company, comments: „Allergic airway diseases have been steadily increasing over the last 60 years and treatment options are so far quite limited. Therefore, a safe and effective primary prophylaxis is a significant unmet medical need. Nowadays, every child in Europe and North America has a 20% risk of developing allergic airway disease and this risk increases up to 70% for children of allergic parents.”

Broad proof-of-concept has been established in relevant animal models and pre-clinical toxicity and safety testing has successfully been completed so that the project is prepared to enter the clinical Phase. “Having met this milestone we are looking forward to discuss the project with investors and established companies for partnering to expedite the clinical development”, states Marion Kauth.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protectimmun Teams Up with Johnson & Johnson Innovation and Imperial College
Company has entered into a research funding agreement with Janssen.
Tuesday, September 29, 2015
Scientific News
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Iron in the Blood Could Cause Cell Damage
Concentrations of iron similar to those delivered through standard treatments can trigger DNA damage within 10 minutes, when given to cells in the laboratory.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
Muscles on-a-Chip
This study may help explain why stem cell-based therapies have so far shown limited benefits for heart attack patients in clinical trials.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!